Cost comparison of drug-drug and drug-condition interactions in patients with painful diabetic peripheral neuropathy treated with pregabalin versus duloxetine

American Journal of Health-System Pharmacy

Volumn 70, Issue 24, 2013, Pages 2207-2217

  Johnston, Stephen S ^a   Udall, Margarita ^b   Cappelleri, Joseph C ^b   Johnson, Barbara H ^a   Shrady, George ^a   Chu, Bong Chul ^a   Silverman, Stuart L ^c  

^a IBM WATSON HEALTH   (United States)

^b PFIZER INC   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; DULOXETINE; PREGABALIN; WARFARIN; 4 AMINOBUTYRIC ACID; ANALGESIC AGENT; DRUG DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BIPOLAR DISORDER; CLOSED ANGLE GLAUCOMA; COMORBIDITY; DIABETIC NEUROPATHY; DRUG CONTRAINDICATION; DRUG COST; FEMALE; HEALTH CARE COST; HUMAN; HYPERTENSION; HYPONATREMIA; KIDNEY DISEASE; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL NEUROPATHY; PREGNANCY; PRESCRIPTION; PREVALENCE; SEIZURE; SKIN MANIFESTATION; STOMACH EMPTYING; SUICIDE; URINE RETENTION; AGED; COHORT ANALYSIS; COMPARATIVE STUDY; ECONOMICS; FACTUAL DATABASE; MIDDLE AGED; RETROSPECTIVE STUDY; UNITED STATES;

AGED; ANALGESICS; COHORT STUDIES; DATABASES, FACTUAL; DIABETIC NEUROPATHIES; FEMALE; GAMMA-AMINOBUTYRIC ACID; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THIOPHENES; UNITED STATES;

EID: 84905070760     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp130088     Document Type: Article

References (33)

1. Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes. 2008; 26:77-82.
2. Duby JJ, Campbell RK, Setter SM et al. Diabetic neuropathy: an intensive review. Am J Health-Syst Pharm. 2004; 61:160-76.
3. Sadosky A, McDermott AM, Brandenburg NA et al. A review of the epidemiology of painful diabetic peripheral neuropathy, postherpetic neuralgia, and less commonly studied neuropathic pain conditions. Pain Pract. 2008; 8:45-56.
4. Ritzwoller DP, Ellis JL, Korner EJ et al. Comorbidities, healthcare service utilization and costs for patients identified with painful DPN in a managedcare setting. Curr Med Res Opin. 2009; 25:1319-28.
5. Fravel MA, McDanel DL, Ross MB et al. Special considerations for treatment of type 2 diabetes mellitus in the elderly. Am J Health-Syst Pharm. 2011; 68:500-9.
6. Triplitt C. Drug interactions of medications commonly used in diabetes. Diabetes Spectr. 2006; 19:202-11.
7. Austin RP. Polypharmacy as a risk factor in the treatment of type 2 diabetes. Diabetes Spectr. 2006; 19:13-6.
8. American Diabetes Association. Standards of medical care in diabetes - 2012. Diabetes Care. 2012; 35(suppl 1):S11-63.
9. Lyrica (pregabalin) package insert. New York: Pfizer Inc.; 2011.
10. Cymbalta (duloxetine) package insert. Indianapolis: Eli Lilly and Company; 2011.
11. Nucynta (tapentadol) package insert. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2012.
12. Classen DC, Pestotnik SL, Evans RS et al. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1997; 277:301-6.
13. Bates DW, Spell N, Cullen DJ et al. The costs of adverse drug events in hospitalized patients. JAMA. 1997; 277:307-11.
14. Cahir C, Fahey T, Teeling M et al. Potentially inappropriate prescribing and cost outcomes for older people: a national population study. Br J Clin Pharmacol. 2010; 69:543-52.
15. Moura CS, Acurcio FA, Belo NO. Drug-drug interactions associated with length of stay and cost of hospitalization. J Pharm Pharm Sci. 2009; 12:266-72.
16. Moura C, Prado N, Acurcio F. Potential drug-drug interactions associated with prolonged stays in the intensive care unit: a retrospective cohort study. Clin Drug Investig. 2011; 31:309-16.
17. Stockl KM, Le L, Zhang S et al. Clinical and economic outcomes associated with potentially inappropriate prescribing in the elderly. Am J Manag Care. 2010; 16:e1-10.
18. Cornell University Law School. 45 CFR 164.514 - other requirements relating to uses and disclosures of protected health information. www.law.cornell.edu/cfr/text/45/164.514 (accessed 2013 Oct 1).
19. Consumer Price Index (CPI). www.bls.gov/ cpi (accessed 2013 Sep 16).
20. Margolis J, Cao Z, Fowler R et al. Evaluation of healthcare resource utilization and costs in employees with pain associated with diabetic peripheral neuropathy treated with pregabalin or duloxetine. J Med Econ. 2010; 13:738-47.
21. Udall M, Harnett J, Mardekian J. Costs of pregabalin or gabapentin for painful diabetic peripheral neuropathy. J Med Econ. 2012; 15:361-70.
22. Harnett J, Margolis J, Cao Z et al. Real-world evaluation of healthcare resource utilization and costs in employees with fibromyalgia treated with pregabalin or duloxetine. Pain Pract. 2011; 11:217-29.
23. Glick HA, Doshi JP, Sonnad SS et al. Economic evaluation in clinical trials. New York: Oxford Univ. Press; 2007:89-113.
24. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ. 2001; 20:461-94.
25. Kleinman LC, Norton EC. What's the risk? A simple approach for estimating adjusted risk measures from nonlinear models including logistic regression. Health Serv Res. 2009; 44:288-302.
26. Duan N. Smearing estimate: a nonparametric retransformation method. J Am Stat Assoc. 1983: 78:605-10.
27. Gore M, Sadosky A, Leslie D et al. Selecting an appropriate medication for treating neuropathic pain in patients with diabetes: a study using the U.K. and Germany Mediplus databases. Pain Pract. 2008; 8:253-62.
28. Institute for Safe Medication Practices. Anticoagulants the leading reported drug risk in 2011. New data from 2011 quarters 3-4. www.ismp.org/quarterwatch/pdfs/2011Q4.pdf (accessed 2012 Aug 8).
29. Stults B, Jones RE. Management of hypertension in diabetes. Diabetes Spectr. 2006; 19:25-31.
30. Summers KH, Puenpatom RA, Rajan N et al. Economic impact of potential drug-drug interactions in opioid analgesics. J Med Econ. 2011; 14:390-6.
31. Pergolizzi JV Jr, Labhsetwar SA, Puenpatom RA et al. Economic impact of potential CYP450 pharmacokinetic drug-drug interactions among chronic low back pain patients taking opioids. Pain Pract. 2012; 12:45-56.
32. Pergolizzi JV Jr, Labhsetwar SA, Puenpatom RA et al. Economic impact of potential drug-drug interactions among osteoarthritis patients taking opioids. Pain Pract. 2012; 12:33-44.
33. Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet. 2007; 370:185-91.